Effectiveness and safety outcomes after long-term (54 weeks) vedolizumab therapy for Crohn's disease: a prospective, real-world observational study including patient-reported outcomes (POLONEZ II).
Liebert A, Kłopocka M, Michalak A, Cichoz-Lach H, Talar-Wojnarowska R, Domz Ał-Magrowska D, Konecki Ł, Filipiuk A, Krogulecki M, Kopertowska-Majchrzak M, Stawczyk-Eder K, Waszak K, Eder P, Zagórowicz E, Smoła I, Wojciechowski K, Drygała S.
Liebert A, et al.
Therap Adv Gastroenterol. 2024 Nov 20;17:17562848241293938. doi: 10.1177/17562848241293938. eCollection 2024.
Therap Adv Gastroenterol. 2024.
PMID: 39575158
Free PMC article.